Objective
Cytotoxic T cells have enormous potential for prophylactic and therapeutic interventions against problematic acute or chronic infections and against malignant tumors. A major obstacle to utilizing them effectively is our limited understanding of the molecular foundation that is necessary for CD8 T cells to fulfil their pleiotropic functions. Equally important is to find solutions supporting the robust and safe induction of large numbers of pathogen- or tumor-specific T cells and strategies for customized generation of T cells equipped with a functional capacity that are optimized to the often contrasting needs of particular diseases. For instance, anti-tumor immunity requires large numbers of highly activated effector T cells, while resting memory cells with high proliferative potential in combination with tissue-resident memory cells are thought to enhance protection against viral infections. Similarly, the challenge in treating chronic infections and tumors is to overcome the hypo-functional “exhausted” stage of T cells, but therapeutic induction of the same mechanisms to attenuate an aggressive T cell response could be vital for treating autoimmunity or immunopathology in fulminant liver or lung infections. Thus, to develop prophylactic or interventional strategies through which qualitative aspects of T cell function can be adjusted is a current key challenge in the immunotherapy and vaccine field. We seek to promote such activities by performing research that aims to significantly augment our comprehension of how molecular particularities translate into functional diversity. By taking advantage of 1) experimental systems that specifically mimic disease relevant T cell phenotypes, 2) approaches to assess molecular diversity at single cell level, 3) effective strategies to alter gene expression, and 4) systematic and hypothesis-driven molecular screening, we anticipate the discovery of new targets to optimize immunotherapies for tumors and chronic infections.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences basic medicine immunology immunotherapy
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
ERC-COG - Consolidator Grant
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) ERC-2017-COG
See all projects funded under this callHost institution
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
80333 Muenchen
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.